FDA Approved: ENSACOVE — Supplemental Application (Xcovery Holdings, Inc.)

View source ↗

Summary

FDA approved ENSACOVE's supplemental application for ensartinib submitted by Xcovery Holdings, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ENSACOVE (ensartinib)

Snippet

SUPPL AP for ENSACOVE (ENSARTINIB)